drugset / Trial / NCT00402337

Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation

NCT00402337

Phase 2 Completed 310 enrolled Ironwood Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to evaluate the efficacy and safety of administration of linaclotide acetate in patients with chronic constipation.

Timeline

Start
2006-11
Primary completion
2007-12
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linaclotide Peptide 72 ug Oral
Comparator Linaclotide Peptide 145 ug Oral
Comparator Linaclotide Peptide 290 ug Oral
Comparator Linaclotide Peptide 579 ug Oral

Indications